We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Three years after launching a combination drug, whose design could extend its patent life, Pfizer has filed a lawsuit to block a generic version of Caduet.
A five-year old patent infringement case filed by Apotex backfired when a federal court dismissed the case and ordered the company to pay $3.1 million in attorneys fees after finding its patent invalid.
A federal antitrust lawsuit filed by drug distributors against Purdue Pharma claims the drug company monopolized the oxycodone market by blocking generic versions of the drug with illegally obtained patents.
Language in newly signed free trade agreements covering data exclusivity and patent extension could delay generic drug entry in foreign markets where access to low-cost medicines is highly needed, a bipartisan group of lawmakers contends.
Health Canada has issued draft guidance on the administration of the amended Patented Medicines (Notice of Compliance) Regulations, which went into effect in October 2006 (IPRM, October 2006).
Three years after launching Caduet, a combination of two blockbuster drugs some say is designed to extend patent life, Pfizer is in litigation to block a generic version of the drug.
A five-year old patent infringement case filed by Apotex backfired when a federal court dismissed the case and ordered the company to pay $3.1 million in attorneys fees after finding its patent invalid.
Teva Pharmaceutical will have partial marketing exclusivity once it launches rabeprazole sodium, a generic version of Eisai’s acid-pump inhibitor drug, Aciphex.
With several pieces of legislation being considered to lower drug spending costs, lawmakers and industry sources see opportunities to overhaul federal healthcare policy to improve the generic drug industry.